Nearly all the meters on pharma's pipeline are reading critical. With licensing and M&A increasingly a series of high-priced auctions, Big Pharma is casting about, often desperately, for new business-development strategies. And one place they're beginning to look is corporate venture capital, traditionally a way to provide drug companies with a window on new technologies. But that means finding a way to break through the seemingly impenetrable wall between corporate venture investing and other corporate and research activities. Thus, companies have embarked on a number of different strategies, ranging from the traditional to the radically new and aggressive. Getting the equity investor and the asset-hungry pharma partner to co-exist peacefully has aroused plenty of both skepticism and confusion Nevertheless, there's still a promising way for drug companies to get value from start-ups beyond mere equity appreciation--investing de-prioritized drug candidates, not merely capital.
by Roger Longman
It’s not as if there are a lot of options.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.
Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.
The Italian drugmaker gets rights to Phase III-ready asset radiprodil.
GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.
GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.
New CEO Renée Aguiar-Lucander is marking her mark.
Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.
